These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 23639500)

  • 1. The new oral anticoagulants in clinical practice.
    Gonsalves WI; Pruthi RK; Patnaik MM
    Mayo Clin Proc; 2013 May; 88(5):495-511. PubMed ID: 23639500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
    Fawole A; Daw HA; Crowther MA
    Cleve Clin J Med; 2013 Jul; 80(7):443-51. PubMed ID: 23821689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
    Akwaa F; Spyropoulos AC
    Hosp Pract (1995); 2013 Feb; 41(1):8-18. PubMed ID: 23466963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
    Gong IY; Kim RB
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S24-33. PubMed ID: 23790595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The laboratory and the new oral anticoagulants.
    Tripodi A
    Clin Chem; 2013 Feb; 59(2):353-62. PubMed ID: 23043068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative management of patients on new oral anticoagulants.
    Lai A; Davidson N; Galloway SW; Thachil J
    Br J Surg; 2014 Jun; 101(7):742-9. PubMed ID: 24777590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical pharmacological aspects of new oral anticoagulants].
    Haschke M
    Ther Umsch; 2012 Nov; 69(11):657-60. PubMed ID: 23117669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New oral anticoagulants for non-valvular atrial fibrillation--safety issues.
    Barry M
    Ir Med J; 2013 Mar; 106(3):69. PubMed ID: 23951972
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
    Levy JH
    Clin Lab Med; 2014 Sep; 34(3):443-52. PubMed ID: 25168936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Management of direct action oral anticoagulants in the peri-operative period and invasive techniques].
    Llau JV; Ferrandis R; Castillo J; de Andrés J; Gomar C; Gómez-Luque A; Hidalgo F; Torres LM;
    Rev Esp Anestesiol Reanim; 2012; 59(6):321-30. PubMed ID: 22633209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug and dietary interactions of the new and emerging oral anticoagulants.
    Walenga JM; Adiguzel C
    Int J Clin Pract; 2010 Jun; 64(7):956-67. PubMed ID: 20584229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
    Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The new oral anticoagulants: a challenge for hospital formularies.
    Merli GJ
    Hosp Pract (1995); 2012 Aug; 40(3):126-8. PubMed ID: 23086101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
    Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bleeding and surgery in the treatment with new oral anticoagulants. The management can be complicated by the lack of specific antidotes].
    Dalén M; Hjemdahl P; Holmström M; Ivert T
    Lakartidningen; 2014 Jun 11-17; 111(24):1064-8. PubMed ID: 25129916
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bleeding complications under oral anticoagulation].
    Beyer-Westendorf J
    Dtsch Med Wochenschr; 2014 Dec; 139(49):2491-3. PubMed ID: 25376450
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
    Hellwig T; Gulseth M
    Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral anticoagulants: the move beyond warfarin.
    Frei J; Carroll VS
    J Neurosci Nurs; 2014 Oct; 46(5):253-5. PubMed ID: 25188682
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.